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8Abbreviations
BMI Body mass index
BSA Bovine serum albumin
CEAD Coulometric electrode array detection
CI Confidence interval
CV Coefficient of variation
DMBA 7,12-dimethylbenzanthracene
EGF Epidermal growth factor
END Enterodiol (lignane-3,3’,9,9’-tetraol)
ENL Enterolactone (3,3’-dihydroxylignano-9,9’-lactone)
FFQ Food frequency questionnaire
GC Gas chromatography
HMR 7’-Hydroxymatairesinol (4,4’,7’-trihydroxy-3,3’-dimethoxylignano-
9,9’-lactone)
HPLC High-performance liquid chromatography
ICC Intra-class correlation coefficient
IGF-I Insulin-like growth factor I
IMS Ion mobility spectrometry
LAR Lariciresinol (3,3’-dimethoxy-7,9’-epoxylignane-4,4’,9-triol)
MS Mass spectrometry
MAT Matairesinol (4,4’-dihydroxy-3,3’-dimethoxylignano-9,9’-lactone)
NADPH Nicotinamide adenine dinucleotide phosphate (reduced form)
NMU N-methyl-N-nitrosourea
OR Odds ratio
PIN Pinoresinol (3,3’-dimethoxy-7,9’:7’,9-diepoxylignane-4,4’-diol)
SEC Secoisolariciresinol (3,3’-dimethoxy-lignane-4,4’,9,9’-tetraol)
SHBG Sex hormone binding globulin
SYR Syringaresinol (3,3’,5,5’-tetramethoxy-7,9’:7’,9-diepoxylignane-4,4’-
diol)
TR-FIA Time-resolved fluoroimmunoassay
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Objective:
Enterolactone, a mammalian lignan, is produced by colonic microflora from its
precursors present widely in food plants. Experimental studies in animals and in
vitro suggest that enterolactone has anticarcinogenic activity. Here, a revised
methodology for serum enterolactone analysis is presented. In addition, the role
of enterolactone as a biological marker and the association between serum
enterolactone and breast cancer risk in a case-control study of Finnish women
were investigated.
Time-resolved fluoroimmunoassay for serum enterolactone:
In its previous version, excessive amounts of enzyme in hydrolysis disturbed the
assay. This study presents a new version of the assay, which exhibits a good corre-
lation with the reference method of gas chromatography-mass spectrometry. This
revised method proved to be a functional tool in epidemiological studies. A fully
automated short time-resolved fluoroimmunoassay for serum enterolactone
using minute sample amounts is also described.
Enterolactone as a biological marker:
In our cross-sectional survey of 2383 Finnish adults, we found a large between-
subject variation in serum enterolactone concentration 0-180 nmol/L. The me-
dian serum enterolactone concentration in men was 14 nmol/L, and in women
17 nmol/L.
The short-term within-subject variation in enterolactone was studied in
serum, in 24-hour urine, and in the spot urine enterolactone:creatinine ratio in
19 volunteers. The variation was large in both serum and urine enterolactone
measurements. To estimate enterolactone concentration within ±50% with 80%
confidence requires three serum or 24-hour urine samples, but 10 spot urine
samples.
In women, serum enterolactone concentration was positively and inde-
pendently associated with vegetable consumption, age, and constipation, and
negatively associated with smoking. In men, multiple regression analyses showed
positive, independent associations with consumption of whole-grain products,
fruit, and berries, and with constipation. However, diet and health-related
variables appeared to explain only a small part of the vast variation between
subjects. A 12-week dietary intervention study with 85 subjects was able to raise
the median concentration of enterolactone from 12 to 20 nmol/L (p = 0.002)
with the aid of a low-fat, high-vegetable diet.
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Enterolactone in breast cancer:
In a Finnish case-control study of 194 breast cancer cases and 208 controls,
serum enterolactone was inversely associated with breast cancer risk. The odds
ratio in the highest quintile of enterolactone concentrations adjusted for all known
risk factors for breast cancer was 0.38 (95% CI 0.18-0.77, p=0.03) compared
with the lowest quintile.
Conclusions:
Time-resolved fluoroimmunoassay is a useful method for serum enterolactone
analysis. To obtain reliable data epidemiological studies should measure entero-
lactone in multiple serum samples. Due to numerous confounding factors, the
value of serum enterolactone measurement as a biological marker of diet is
limited. In this case-control study serum enterolactone was inversely associated
with breast cancer risk.
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Tiivistelmä (Finnish abstract)
Enterolaktoni on lignaaneihin kuuluva yhdiste. Monet ravintona käytettävistä
kasvikunnan tuotteista sisältävät enterolaktonin esiasteita, joista suoliston bak-
teerikanta tuottaa enterolaktonia. Kokeelliset eläin- ja solukokeet osoittavat, että
enterolaktonilla saattaa olla syövältä suojaavia vaikutuksia. Tässä tutkimuksessa
kehitettiin määritysmenetelmää seerumin enterolaktonipitoisuudelle, tutkittiin
enterolaktonipitoisuuksien vaihtelua ja pitoisuutta selittäviä tekijöitä suomalais-
väestössä, ja selvitettiin seerumin enterolaktonipitoisuuden yhteyttä rintasyöpä-
riskiin.
Seerumin enterolaktonin aikarajoitteinen fluoroimmunomääritys:
Tässä työssä esitettiin aikarajoitteisen fluoroimmunomäärityksen uusi versio.
Uuden version tulokset korreloivat hyvin viitemenetelmän (kaasu kromatografia
yhdistettynä massaspektrometriaan) kanssa. Lisäksi työssä osoitettiin, että edeltä-
vän version virheelliset tulokset johtuivat hydrolyysissä käytetystä suuresta entsyy-
mimäärästä, joka häiritsi määritystä. Uusi menetelmä sopii hyvin epidemiologi-
siin tutkimuksiin, joissa näytteiden lukumäärä usein on suuri. Työssä esitettiin
myös täysin automatisoitu pikamenetelmä, jota voidaan käyttää hyvin pienillä
näytemäärillä.
Enterolaktoni biologisena merkkiaineena:
Yli 2000 suomalaisen aikuisen poikkileikkaustutkimus osoitti, että seerumin en-
terolaktoni pitoisuudella on suuri vaihteluväli, 0-180 nmol/l. Enterolaktonin
mediaanipitoisuus miehillä oli 14 nmol/l, ja naisilla 17 nmol/l. Naisilla seeru-
min enterolaktonipitoisuuteen vaikuttavia tekijöitä olivat ikä, ummetus ja tupa-
kointi, sekä ravintotekijöistä vihannesten kulutus. Miehillä pitoisuuteen vaikutti-
vat täysjyvätuotteiden ja marjojen kulutus sekä ummetus. Yllätävää oli, että ruoka-
valiolla ja terveyteen liittyvillä muuttujilla pystyttiin selittämään vain pieni osa
seerumin enterolaktonipitoisuuksien laajasta vaihtelusta.
Enterolaktonin seerumipitoisuuden, erityksen vuorokausivirtsaan ja kertavirt-
sanäytteen enterolaktoni:kreatiniini suhteen lyhyen aikavälin yksilönsisäistä vaih-
telua tutkittiin 19 vapaaehtoisella. Vaihtelu oli huomattavaa kaikissa näytemuo-
doissa. Vallitsevan pitoisuuden arviointi ±50% tarkkuudella ja 80% varmuudella
vaatii kolme seerumi- tai vuorokausivirtsanäytettä, mutta kymmenen kertavirt-
sanäytettä.
Ruokavalion muuttaminen vähentämällä rasvan osuutta ja lisäämällä kasvisten
kulutusta nosti seerumin enterolaktonin mediaanipitoisuutta 85 koehenkilöllä
12:sta 20:een nmol/l (p = 0.002).
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Enterolaktoni ja rintasyöpä:
Seerumin enterolaktonipitoisuuden ja rintasyövän välistä yhteyttä tutkittiin tapa-
us-verrokki tutkimuksessa, johon osallistui 194 rintasyöpään sairastunutta naista
ja 208 tervettä suomalaisnaista. Tutkimus osoitti, että niillä naisilla, joilla seeru-
min enterolaktonipitoisuus oli matala, oli suurentunut riski sairastua rintasyö-
pään.
Päätelmät:
Seerumin enterolaktonipitoisuuden aikarajoitteinen fluoroimmunomääritys on
käyttökelpoinen menetelmä seerumin enterolaktonin analytiikassa. Koska entero-
laktonipitoisuus vaihtelee suuresti päivästä toiseen, luotettavien tulosten saamiseksi
pitäisi epidemiologisissa tutkimuksissa jokaisesta koehenkilöstä olla käytettävissä
useita seeruminäytteitä. Lukuisista sekoittavista tekijöistä johtuen seerumin en-
terolaktonipitoisuus ei ole käyttökelpoinen ravinnonkäytön merkkiaine. Tapaus-
verrokki tutkimuksessa matalaan seerumin enterolaktonipitoisuuteen liittyi
suurentunut rintasyöpäriski.
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Introduction
Breast cancer is the predominant cancer type in women in Finland and in other
industrialized countries. Since the 1950s, the age-adjusted incidence of breast
cancer has increased approximately 1% per year. In 2004, over 3800 women were
predicted to be diagnosed with breast cancer (Finnish Cancer Registry 2004).
Several factors have been associated with an increased risk of breast cancer. Family
history accounts for about 10% of all cases. Both endogenous and exogenous
hormonal factors, including early menarche and late menopause, nulliparity or
late age at first full-term pregnancy, postmenopausal obesity, and hormone
replacement therapy, as well as a low level of physical activity increase the risk of
breast cancer. However, in at least 50% of breast cancer cases, none of these risk
factors applies, and the etiology remains obscure (Johnson-Thompson et al. 2000).
Diet could be an important component in explaining the unknown etiology.
Alcohol intake is the best-established specific dietary risk factor for breast cancer;
even moderate alcohol intake increases the risk of the disease. Results for the
alleviating impact of vegetables, fruit, and dietary fiber are inconsistent, and at
most suggest a modest reduction in the risk of breast cancer (Willett 2001).
Lignans, plant-derived compounds of dietary origin, are mainly found in
wholegrains, berries, and some fruits and vegetables (Mazur et al. 1998). Already
in the early 1980s, excretion of enterolactone (ENL, 3,3’-dihydroxylignano-9,9’-
lactone), the most abundant lignan in humans, was observed to be lower in
women with diagnosed breast cancer than in healthy women (Adlercreutz et al.
1982). Two hypothesis were presented: lignans are the protective compounds in
wholegrains, berries, and some fruits and vegetables (Adlercreutz et al. 1982),
and ENL is a biological marker of a healthy vegetable- and grain-based diet (Adler-
creutz 1984). This work searched for answers to either support or oppose these
hypotheses.
The first step here was to establish a method suitable for the analysis of ENL
in large epidemiological studies. Time-resolved fluoroimmunoassay (TR-FIA)
is a technique that offers specificity, a high rate of sample throughput, and
comparatively low costs (Hemmilä 1988, Dickson et al. 1995). This work is a
continuation of the earlier effort to establish a functioning TR-FIA for serum
ENL (Adlercreutz et al. 1998).
After a suitable method was devised, the characteristics of ENL as a biological
marker were examined. This included analyses of the biological variation.
Knowledge of the magnitude of biological variation is essential when conducting
epidemiological studies because analytes with large within-subject variation
almost always show weak associations with any given disease (blurring = bias
towards the null) (Vineis 1997). Before the present study, no information on the
biological variation of ENL measurements in Finnish subjects existed. In
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addition, this work studied the role of diet on serum ENL levels in cross-sectional
and intervention studies. Cross-sectional analysis of the determinants of serum
ENL concentration reveals, whether ENL serves as a biological marker of any
food item(s) and uncover possible confounding factors. In light of low serum
ENL concentration being a risk factor of many diseases, it is important to deter-
mine whether dietary changes can raise ENL levels in a population. This
was examined by the analyzing serum ENL in a dietary intervention study of a
Finnish population.
Finally, the relationship between ENL and the risk of breast cancer was eluci-
dated in a case-control study of a population in northeastern Finland.
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Review of the literature
Lignans
Definition
The term “lignan” was introduced in 1936 for a class of compounds with a
common feature of two C6C3 (phenyl propane) units linked at the central carbon
atom of the side chain (Howarth 1936). Lignan structures can be divided into
dibenzylbutanes, bibenzylbutyrolactones, tetrahydrofurans, arylnaphtalenes, furo-
furans, and tetrahydrofurans (Ayres et al. 1990). Lignans are often classified as
mammalian or plant lignans. Mammalian lignans have been identified in mam-
malians only and they are formed from plant lignans by the intestinal microflora.
Plant lignans
In plants, lignans are involved in plant defense, having antioxidant, antifungal,
antibacterial, antiviral, insect antifeedant, phytotoxic, and cytotoxic properties
(Kwon et al. 2001). Many drugs in traditional oriental medicine contain lignans
in high quantities (Nishibe 1993). Some natural lignans have clinical use also in
Western medicine, such as the antiviral podophyllotoxin for the treatment of
venereal warts (Ayres et al. 1990).
Lignans occur widely in nature (Davin et al. 2000) and are therefore ubiqui-
tous in the human diet. Matairesinol (MAT, 4,4’-dihydroxy-3,3’-dimethoxy-
lignano-9,9’-lactone) and secoisolariciresinol (SEC, 3,3’-dimethoxy-lignane-
4,4’,9,9’-tetraol) have been quantified in numerous food items (Mazur et al.
1998). In Western diets, SEC is more abundant than MAT. In the Finnish diet
the main sources of SEC are fruit and berries, whereas MAT mostly derives from
whole grains, mainly rye (Kilkkinen et al. 2003a). The main sources of MAT and
SEC for American women are fruits, grain products, and berries (de Kleijn et al.
2001), and for Dutch women grain products, fruit, and wines (Boker et al. 2002).
The SEC content of flaxseed is exceptionally high (Mazur et al. 1998).
Knowledge of the occurrence of other lignans in foods is limited; whole grain
is a rich source of pinoresinol (PIN, 3,3’-dimethoxy-7,9’:7’,9-diepoxylignane-
4,4’-diol), syringaresinol (SYR, 3,3’,5,5’-tetramethoxy-7,9’:7’,9-diepoxylignane-
4,4’-diol), and lariciresinol (LAR, 3,3’-dimethoxy-7,9’-epoxylignane-4,4’,9-tri-
ol) (Heinonen et al. 2001), and PIN is present in high quantities in olive oil
(Owen et al. 2000). Thus far, no study has identified ENL or enterodiol (END,
lignane-3,3’,9,9’-tetraol) in plants.
Mammalian lignans
ENL and END were the first lignans identified in mammals (Setchell et al. 1980b,
Stitch et al. 1980). Instead of being endogenously synthesized, they are of
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dietary origin, with plant lignans as their precursors (Axelson et al. 1982). No
lignan biosynthesis is known to occur in mammals.
Dietary precursors of mammalian lignans
To date, five dietary lignans have been identified as ENL precursors (Fig. 1): SEC
(Axelson et al. 1982), MAT (Borriello et al. 1985), LAR, SYR, and PIN (Hei-
nonen et al. 2001). 7’-Hydroxymatairesinol (HMR, 4,4’,7’-trihydroxy-3,3’-
dimethoxylignano-9,9’-lactone) (Saarinen et al. 2000) and arctigenin (Heino-
nen et al. 2001) are converted to mammalian lignans, but they are not known to
occur in plants commonly used as human foods.
Lignans and intestinal microflora
Plant lignans occur as glycosides and their bioavailability requires hydrolysis of
the sugar moiety for uptake into the circulation. Hydrolysis may occur in the
intestinal lumen by bacterial β-glucosidases or in enterocytes by cytosolic β-glu-
cosidases (Setchell et al. 2002). In the intestine, plant lignans become substrates
for the metabolism to mammalian lignans. According to studies in pigs,
metabolism of plant lignan glucosides to END and ENL (Glitsø et al. 2000) and
absorption of END and ENL occur in the large intestine (Bach Knudsen et al.
2003). Free plant lignans may also be absorbed unchanged, but they are present
in urine only in small quantities, in contrast to mammalian lignans, which form
the majority of circulating and urinary lignans (Bannwart et al. 1984, 1989,
Nurmi et al. 2003a).
The conversions of plant lignans to END and ENL, and of END to ENL are
not spontaneous, but require the presence and activity of gut bacteria (Axelson et
al. 1981, Setchell et al. 1981, Borriello et al. 1985). END and ENL production
occurs under both aerobic and anaerobic conditions (Borriello et al. 1985).
Bacterial strains responsible for the conversion of plant lignans to ENL are not
fully identified. One study suggested an essential role for Clostridia (Setchell et al.
1981), but this was not confirmed (Borriello et al. 1985). Subsequent studies have
identified the Gram-positive anaerobic species Peptostreptococcus and Eubacterium,
which are capable of transforming SEC to END (Wang et al. 2000), and Enterococcus
faecalis, which is responsible for the transformation of (+)-PIN to (+)-LAR (Xie et
al. 2003). The microflora influences the ratio of ENL to END formed in the gut
(Setchell et al. 1981). In Western populations, ENL seems to be 3-12 times more
abundant than END (Adlercreutz et al. 1986a, Kirkman et al. 1995, Lampe et al.
1999). In a study with five men, the production of END recovered more rapidly
after antimicrobial treatment than that of ENL, and the relative abundance of END
became greater ( Setchell et al. 1981, Adlercreutz et al. 1986a).
Recovery of mammalian lignans
In a metabolic study with pigs, the conversion of mammalian lignan precursors
to ENL was on average 48% and 60% with two different diets. The calculated
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Fig. 1. Metabolism of plant lignans to END and ENL.
References: Heinonen et al. 1999.
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bioavailability of MAT and SEC was higher (75-77%) than that of LAR, PIN,
and SYR (10-19%) (Bach Knudsen et al. 2003). In human subjects, the recovery
of dietary lignans in urine varies widely ( Nesbitt et al. 1999, Mazur et al. 2000).
In vitro, after incubation of plant lignans for 24 h in human fecal inoculum, the
recovery was dependent on the individual differences of the fecal flora and on the
compound of interest, ranging from 4% (SYR) to 101% (LAR) (Heinonen et al.
2001). The recovery may also vary due to individual differences in phase I and II
metabolism of lignans.
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Table 1. Study design for application of biological markers in epidemiology.
STUDY DESIGN AIM
1. Laboratory studies To develop a method for measurement of the marker
2. Transitional studies To determine
Developmental studies Biological relevance in disease development
Pharmacokinetics of the marker
Optimal conditions for collecting and storing
biological specimens
Characterization studies Levels of marker in a population and its subgroups
Components of variation and the reliability of the
measurement
Factors confounding and modifying the level of the
marker
Applied transitional studies Relationship between the marker and exposure
Whether intervention is efficacious in changing the level
of the marker
3. Etiological studies: To determine
Observational studies
Ecological Geographical differences
Timetrends in the level of the marker and in disease
prevalence and incidence
Case-control and cohort Association between marker and risk of disease
Experimental studies Causality
4. Public health applications To affect policy-making decisions
To incorporate biomarkers in
Screening
Clinical prevention
References: Rothman et al. 1995, Toniolo et al. 1997
Serum enterolactone as a biological marker
What is a biological marker?
Definition
A biological marker, or commonly abbreviated to biomarker, is any substance or
process that can be measured in the human body or in its products and may
influence or predict the incidence of disease (Toniolo et al. 1997). A biological
marker is not a diagnostic test but an indicator of an increased or decreased risk of
disease (Grandjean 1995).
Application of biological markers in epidemiology
Laboratory studies form the basis for research of biological markers by creating a
method for the measurement of the marker. Transitional studies provide a bridge
between the use of biological markers in laboratory experiments and their use in
cancer epidemiology (Schulte et al. 1997) (Table 1).
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Laboratory studies – methods available for serum enterolactone
measurements
Chromatographic methods
Several chromatographic methods have been developed for the analysis of ENL in
plasma. The first methods were based on gas chromatography (GC) with mass
(MS) or ion mobility (IMS) spectrometry. These methods face the problem of
complex sample pretreatment and require a large plasma volume for the analysis.
Later methods that utilize high-performance liquid chromatography (HPLC)
combined with coulometric electrode array detection (CEAD) or MS have been
able to escape these problems. The available methods and their sample volume
requirements are summarized in Table 2.
Table 2. Chromatographic methods for the analysis of ENL in serum/plasma.
Reference Instrumentation Sample volume
required (mL)
Setchell et al. 1983 GC-MS1 5.0-10
Adlercreutz et al. 1993b GC-MS/SIM 4.0
Atkinson et al. 1993 GC-IMS 1.0
Gamache et al. 1998 HPLC-CEAD 0.20
Nurmi et al. 1999 HPLC-CEAD 0.50
Valentin-Blasini et al. 2000 HPLC-MS/MS 1.0
Franke et al. 2002 HPLC-DAD-MS 0.45
Grace et al. 2003 HPLC-MS/MS 0.20
Smeds et al. 2003 HPLC-MS/MS 0.30
Abbreviations: GC, gas chromatography; MS, mass spectrometry; SIM, selected ion
monitoring; IMS, ion mobility spectrometry;
HPLC, high-performance liquid chromatography; CEAD, coulometric electrode array
detection; DAD, diode array detection
Immunological methods
Immunological methods allow the generation of highly automatic and rapid yet
specific analyses. The only available immunological method for measuring ENL
in serum is TR-FIA (Adlercreutz et al. 1998). TR-FIA combines the advantages
of nonradioisotopic assays, high sensitivity, and low background interference
(Hemmilä 1988, Dickson et al. 1995). In the assay, a synthetic ENL derivative
coupled with a Europium label competes for binding to the antiserum with the
ENL present in the sample. After the reaction is completed, the bound Euro-
pium ions are dissociated from the chelates by enhancement solution. In solu-
tion, Europium ions form highly fluorescent complexes that can be measured by
fluorometry.
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TR-FIA for serum ENL had already been published (Adlercreutz et al. 1998)
and taken into use by the authors before this work. The publication describes the
early, original version of the assay, although this was no longer in use at the time
of publication. Already before the publication, creation of a sample pretreatment
that is convenient in practical work became necessary. This was achieved by
reducing the volume of the hydrolysis reagent, which enabled hydrolysis and
ether extraction to be performed in disposable glass tubes. The volume of diethyl
ether was simultaneously reduced, shortening the time required for the
extraction. This work started with the unexpected finding that these two versions
of the assay gave unequal results.
Transitional studies
Metabolism of enterolactone
Kinetics
The elimination half-life of ENL in the human body is unknown. This may partly
depend on the lack of sufficiently large amounts of pure ENL. A single dose of
lignan-rich food increased ENL concentration in plasma continuously, with no
peak, up to the last time-point (24 h) (Mazur et al. 2000, Morton et al. 1997a,
Nesbitt et al. 1999). In fecal incubations of SEC diglycoside, demethylated and
dehydroxylated metabolites first appeared after 48 h (Wang et al. 2000). In pigs,
serum ENL concentration reached a steady state of ~400 nmol/L three days after
the introduction of a lignan-rich diet (Bach Knudsen et al. 2003).
Phase I metabolism
Phase I metabolism of ENL occurs before conjugation (Phase II metabolism) in
microsomal enzymes, which are present in the highest amounts in the liver and
gastrointestinal tract. Several oxidative metabolites of ENL and END have been
detected in human urine (Fig. 2) (Jacobs et al. 1999a). In vitro, human micro-
somes were unable to produce two of the compounds (4-OH-ENL and 4‘-OH-
ENL), and these seem to be intermediates of the bacterial conversion of SEC
and/or MAT to ENL (Jacobs et al. 1999b). The proportion of the Phase I me-
tabolites of ENL and END is estimated to be <5% of all lignans present in urine
(Jacobs et al. 1999a). The microsomal incubation of END did not yield ENL,
indicating that this oxidation only occurs via intestinal bacteria.
Phase II metabolism
Free, absorbed lignans are readily conjugated to glucuronides and sulfates, which
increases their water solubility and decreases the passive penetration of cell
membranes. The conjugation is achieved with specific enzymes: cytosolic
sulfotransferases and glucuronosyltransferases (Ritter 2000, Glatt et al. 2001).
The enzymes are present ubiquitously in tissues but are enriched in the intestinal
wall and in the liver. In vitro, HepG2 hepatic cancer cells as well as MCF-7 breast
22 Fig. 2. Phase I metabolism of END and ENL.
References: Jacobs et al. 1999a, 1999b.
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cancer cells conjugate ENL effectively (Adlercreutz et al. 1992, Mousavi et al.
1992). The activity of the subtypes of sulfotransferases and glucuronosyltrans-
ferases shows marked individual variation (Glatt et al. 2001), resulting in differ-
ences in the proportions of ENL glucuronide and sulfate conjugates in human
plasma (Adlercreutz et al. 1993b) and urine (Adlercreutz et al. 1995b).
Distribution
After absorption and first-pass metabolism in the intestinal tract and in liver,
lignans are distributed throughout the body via circulation. In plasma, 55-95%
(mean 79%, n=28) of ENL occur as glucuronides, and 5-45% (mean 21%) are present
in free form or as sulfates (Adlercreutz et al. 1993b). In circulation, ENL may bind
to plasma proteins. In vitro, free ENL and END in >1 µmol/L concentrations
displace endogenous steroid hormones from sex hormone binding globulin (SHBG)
(Martin et al. 1996, Schottner et al. 1998). From blood vessels, lignans may enter
several tissues. ENL in human subjects occurs in some tissues in relatively high
quantities: prostate tissue 93±25 nmol/L (mean±standard error), n=10 (Hong
et al. 2002), prostatic fluid 230 (0-2100) nmol/L (mean (range)), n=83 (Morton
et al. 1997a), and semen 180 (63-560) nmol/L (mean (range)), n=6 (Dehennin
et al. 1982). ENL is also present in breast tissue (mean 20 pmol/g, n=14) (Har-
greaves et al. 1999). It accumulates in breast cyst fluid. In type I cysts, the mean
ENL concentration was 140 nmol/L (standard error 12) nmol/L, n=141, in type
II cysts 17 (5.7) nmol/L, n=50 (Boccardo et al. 2003). The disposition of the
metabolites of 3H-SEC diglycoside has been studied in rats; the main targets were
the liver, kidney, gastrointestinal tract, uterus, and ovaries. Chronic (>10 d) expo-
sure to lignans resulted in increased lignan disposition in liver and adipose tissue
compared with acute exposure (Rickard et al. 1998).
Excretion
Conjugated lignans can be excreted to either urine or bile. Of the urinary
lignans, 84-99% (mean 92%, n=6) occur as glucuronides (Adlercreutz et al. 1995b).
Direct evidence on the excretion of conjugated ENL and END into the bile exists
only for rats, in which the amounts of ENL excreted into bile and urine are
almost equal (Axelson et al. 1981). In the intestine, the excreted lignans can be
reabsorbed (enterohepatic circulation) or excreted in feces. In rats treated with
3H-SEC diglycoside, >50% of radioactivity was found in feces and 28-32% in
urine at 48 h (Rickard et al. 1998). Of the fecal lignans, the majority occur as
plant lignans and END (Adlercreutz et al. 1995a).
Potential mechanisms of action of enterolactone, in vitro and in vivo
Estrogenic and antiestrogenic effects in vitro
1. Activation of estrogen receptors
Most in vitro studies have examined the estrogenicity of ENL by a somewhat
unspecific measurement, by studying the effect of ENL on the growth of
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estrogen-dependant breast cancer cells. The results are diverse, and here this issue
is simplified by considering only the results obtained with ENL in possibly physio-
logical ≤1 µM concentrations. At these concentrations, ENL alone had either a
stimulatory or no effect on cell growth on estrogen dependant cell lines MCF-7
and T47D (Welshons et al. 1987, Mousavi et al. 1992, Wang et al. 1998a). In
the presence of estradiol, ENL either inhibited (Mousavi  et al. 1992) or had no
effect (Wang et al. 1998a) on cell growth. ENL mildly increased estrogen-
responsive pS2 protein expression, a measurement perhaps more specific to estro-
gen receptor activation (Sathyamoorthy et al. 1994). A later study, by contrast,
found no transcriptional response of either human estrogen receptor α or β. The
presence of estradiol did not alter the results (Saarinen et al. 2000).
2. Inhibition of estrogen synthetase (aromatase)
Aromatase belongs to the cytochrome P450 enzyme system and catalyzes the
conversion of androgens to estrogens (androstenedione to estrone and testo-
sterone to estradiol). In vitro ENL has been able to inhibit human aromatase in
placental microsomes (Adlercreutz et al. 1993a) and several cell lines (Adler-
creutz et al. 1993a, Wang et al. 1994, Saarinen et al. 2002a). Concentrations
needed for 50% enzyme inhibition were 14 µM in placental microsomes (Adler-
creutz et al. 1993a), 74 µM in human preadipocytes (Wang et al. 1994), and 8.9
mM in embryonic kidney cells (Saarinen et al. 2002a). At a 1 µM concentration,
ENL reached 22-27% inhibition of aromatase in human chorion carcinoma cells
(Adlercreutz et al. 1993a), 3% inhibition in preadipocytes (Wang et al.1994),
and 6% inhibition of placental aromatase (Adlercreutz et al. 1993a).
3. Inhibition of 17β-hydroxysteroid dehydrogenase
17β-hydroxysteroid dehydrogenase is the enzyme responsible for the conversion
of estrone to estradiol and androstenedione to testosterone. At 100 µM, ENL
showed a 98% inhibition of the enzyme in human genital skin fibroblasts (Evans
et al. 1995). No information exists on the inhibitory effect of ENL at lower,
physiological concentrations.
4. Stimulation of SHBG synthesis
ENL stimulated SHBG synthesis in HepG2 cells in a dose-dependant manner at
all concentrations tested (starting at 1 µM) (Adlercreutz et al. 1992).
Estrogenic and antiestrogenic effects in vivo
1. Animal studies
The estrogenic activity of ENL has been assessed in animal studies by its impact
on uterine weight. In immature female mice and rats, neither subcutaneous ENL
nor oral HMR demonstrated any detectable effect on uterine growth (Setchell et
al. 1981, Saarinen et al. 2001). In contrast, chronic treatment with ENL showed
antiestrogenic effects in rats by reducing relative uterine weight (Saarinen et al.
2002a). The mechanism behind this finding remains unclear. In a short-term
experimental study by the same authors, ENL and other lignans showed no aro-
matase inhibition (Saarinen et al. 2002a).
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2. Human studies
In a cross-sectional study with 34 premenopausal women, urinary ENL excretion
correlated negatively with plasma percentage of free estradiol, and END with
plasma free estradiol. Plasma SHBG had a positive correlation with urinary ENL
excretion (Adlercreutz et al. 1987). In postmenopausal women, a dietary inter-
vention with 5 or 10 g of flaxseed per day reduced serum concentrations of 17β-
estradiol and estrone sulfate (Hutchins et al. 2001). The changes in sex hormone
levels may result from the effects of ENL on estrogen biosynthesis or from the
increased fecal excretion of estrogens due to the dietary fiber associated with the
lignans (Goldin et al. 1981). In premenopausal women, by contrast, 10 g of
flaxseed per day did not affect sex hormone or SHBG levels (Phipps et al. 1993).
Antioxidativity
1. In vitro
Free ENL and END have shown antioxidant activity in vitro only at supraphysio-
logical concentrations (Kitts et al. 1999, Pool-Zobel et al. 2000, Prasad 2000).
When the potency of ENL to inhibit lipid peroxidation in rat liver microsomes
was examined, a 50% inhibitory effect was achieved at a concentration of 16 µM
(Saarinen et al. 2000).
2. In vivo
Research on the ability of ENL to function as an antioxidant in vivo is sparse. A
study on ENL and F2-isoprostanes, a measure of lipid peroxidation, suggested an
antioxidant activity of ENL. A low serum ENL concentration was associated with
increased plasma F2-isoprostanes in a cross-sectional study of 100 Finnish men.
The association between ENL and F2-isoprostanes remained after adjustment for
selenium and alcohol intake and plasma concentrations of homocysteine, alpha-
tocopherol, β-carotene, ascorbic acid, and dietary folate (Vanharanta et al. 2002b).
In contrast, a dietary intervention with rye crisp breads did not affect the anti-
oxidative capacity of plasma. An explanation for the negative result may be that
the average serum ENL concentrations were low and changed only slightly, from
8.8 to 10.7 nmol/L (Pool-Zobel et al. 2000).
Effects on other hormones, enzymes, and growth factors
1. Prolactin
In 28 postmenopausal women, consumption of 10 g of flaxseed for seven weeks
increased serum prolactin concentration by an unknown mechanism (Hutchins
et al. 2001). The same effect was not observed in premenopausal women (Phipps
et al. 1993), nor was statistical significance reached in rats treated with peroral
ENL (Saarinen et al. 2002a).
2. 5α-reductase
5α-reductase converts testosterone into a more potent androgen, 5α-dihydro-
testosterone. ENL was shown to be an inhibitor of the enzyme in benign prostate
hyperplasia tissue homogenate with an IC50 concentration of 14 µM (Evans et al.
1995).
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3. Phase II detoxifying enzymes
Many potentially carcinogenic compounds become relatively inert after conjuga-
tion with detoxifying phase II enzymes, such as NADPH (reduced form of nico-
tinamide adenine dinucleotide phosphate):quinone reductase (Ross et al. 2000).
ENL effectively induced NADPH:quinone reductase in human Colo205 colon
carcinoma cells at concentrations ≥0.1 µM (Wang et al. 1998b).
4. Growth factors
High plasma levels of insulin-like growth factor I (IGF-I) have been linked to
increased risk of several cancer types, including breast, prostate, and colorectal
cancers (Giovannucci 1999). In vivo, an intake of flaxseed or purified SEC digly-
coside in rats reduced plasma IGF-I concentrations (Rickard et al. 2000). In
addition, dietary flaxseed was able to reduce the expression of IGF-I, epidermal
growth factor (EGF) receptor, and extracellular levels of vascular endothelial growth
factor in a primary tumor site of established human breast cancer in nude mice
(Chen et al. 2002, Dabrosin et al. 2002). In MDA-MB-468 breast cancer cells,
however, ENL demonstrated no effect on EGF transcription (Schultze-Mosgau
et al. 1998).
Adverse effects and toxicity
1. Genotoxicity
In most studies, no signs of genotoxicity have been observed at ≤100 µM ENL
(Setchell et al. 1981, Kulling et al. 1998, Pool-Zobel et al. 2000). One study
did, however, show toxicity of ENL on human colon carcinoma cell growth at
concentrations of ≥1 µM (Wang et al. 1998b).
2. Reproductive health
a. Menstrual cycle
A 10-g daily dose of flaxseed in healthy women caused longer luteal phase
lengths and higher luteal phase progesterone/estradiol ratios and midfol-
licular phase testosterone concentrations than a control diet, but no
anovulatory cycles (Phipps et al. 1993). By contrast, rats exposed to 10%
flaxseed either at an early age, during pregnancy and lactation, or in adult-
hood had an increased risk of menstrual irregularities or persistent diestrus
(Orcheson et al. 1998, Tou et al. 1998).
b. Infertility
No evidence of an association between human infertility and lignans exists.
Although ENL is present in human semen in relatively high concentra-
tions, no changes in the proportion of motile spermatozoa or in sperm
motility of ejaculates occurred when mixed with 1 µM concentrations of
synthetic ENL (Dehennin et al. 1982). In rats, flaxseed had no effect on
spermatogenesis (Sprando et al. 2000).
c. Fetal malformations
Exposure of human subjects to lignans during pregnancy does not appear
to pose a risk; no reports have emerged of any adverse effects. In rats, a 10%
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flaxseed diet had no impact on pregnancy outcome other than lowering
birth weight and suggesting estrogenic effects. In contrast, 5% flaxseed or
an equivalent dose of SDG indicated antiestrogenic effects (Tou et al. 1998).
Ingestion of flaxseed during lactation deemed safe (Ward et al. 2001).
Summary
In man, the evidence of ENL bioactivity is limited. The detectable actions of
ENL in vitro occur mainly at supraphysiological concentrations, and the rele-
vance of these findings on health is unclear. In addition, most studies examine
the function of free ENL, which forms only a minor proportion of the circulating
ENL. Future studies should thus examine the bioactivity of ENL conjugates as
well. Our lack of knowledge about ENL bioactivity does not necessarily indicate
that ENL is inactive in the body. The concentrations of ENL in tissues are mostly
unknown and may be relatively high, particularly in the gastrointestinal tract and
in the liver, which are the major sites for the synthesis of SHBG and growth
factors. Because food is consumed daily, dietary compounds with even weak
activity, may be of importance in human health and prevention of diseases.
Serum enterolactone concentrations in Finnish and other populations
The amounts of circulating ENL in different populations have been explored in
several studies (Tables 3 and 4). Diversity is present in serum ENL concentrations
in Finnish subjects. A likely explanation for this is that most studies have small
subject pools, and thus, may not represent the group of interest well. In addi-
tion, differences in sex, age, and dietary habits may explain the disparities. Serum
ENL concentrations also seem to differ between subjects of different nationali-
ties. However, no studies have compared these differences using appropriate
statistical methods. Several studies have examined ENL excretion in urine in
different populations. For a review of these studies, please refer to the recent
thesis by Niina Saarinen (2002b).
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Table 3. Reported serum/plasma ENL concentrations in healthy Finnish adults.
Reference Diet Subjects n Method Function ENL (nmol/L)
Uehara et al. 2000a habitual females (F) 87 TR-FIA median 21
Juntunen et al. 2000 habitual F 21 TR-FIA mean 39
habitual males (M) 18 TR-FIA mean 28
Adlercreutz et al. 1993b omnivore premenopausal F 10 GC-MS mean 28
omnivore postmenopausal F 4 GC-MS mean 47
vegetarian premenopausal F 10 GC-MS mean 90
vegetarian premenopausal F 4 GC-MS mean 660
Table 4. Reported serum/plasma ENL concentrations in healthy adults in different countries.
Reference Diet Country Subjects n Method Function ENL (nmol/L)
Brzezinski et al. 1997 habitual Israel F 78 GC-MS mean 160
Morton et al. 1997b habitual Hong Kong M 53 GC-MS mean 21
habitual Portugal M 50 GC-MS mean 13
habitual US M 36 GC-MS mean 13
Zeleniuch-Jacquotte et al. 1998 habitual US F 60 GC-MS median 23
Uehara et al. 2000a habitual Japan F 111 TR-FIA median 7.7
Franke et al. 2002 habitual Hawaii F&M 20 HPLC-MS mean 19
Horner et al. 2002 habitual US F&M 193 TR-FIA geometric 14
(high/low vegetable intake) mean
Morton et al. 2002 habitual UK M 43 GC-MS median 19
habitual UK F 133 GC-MS median 16
habitual Japan M 102 GC-MS median 11
habitual Japan F 125 GC-MS median 11
Grace et al. 2003 habitual UK F&M 300 HPLC-MS median 14
Valentin-Blasini et al. 2003 habitual US F&M 208 HPLC-MS mean 12
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Reliability of enterolactone measurements in biological samples
The long-term (two years) reliability of serum ENL measurements proved not to
be very good in one American population (intra-class correlation coefficient,
ICC = 0.55) (Zeleniuch-Jacquotte et al. 1998). The long-term reliability of over-
night urine ENL:creatinine ratio was studied in a Dutch population (den Tonke-
laar et al. 2001); for four samples collected with a lag-time of 1–4.5 years the
reliability was even lower, with the correlation coefficients varying between 0.27
and 0.58. Two studies have examined the short-term reliability of serum ENL. In
American subjects, the Pearson correlation coefficient for ENL concentrations of
two plasma samples collected on consecutive days was 0.84 (Horner et al. 2002).
In Hawaiian volunteers, the ICC of three overnight urine samples collected eight
days apart was 0.74 (Franke et al. 2002). No information on the reliability of
ENL measurements in Finnish subjects is available.
The most common way to store the samples is at –20°C. At this temperature,
serum ENL concentration is known to stay unchanged for at least ten years (Adler-
creutz H., pers. comm.).
Only one recent study has examined and found a highly significant correla-
tion of ENL levels in urine and serum samples from the same person (Valentin-
Blasini et al. 2003). No studies appear to have compared the reliability of ENL
measurement in blood and urine.
Applied transitional studies
Determinants of enterolactone
Several studies have reported an association between plasma or serum and urine
ENL and intake of different dietary and other variables. Table 5 summarizes these
results.
Factors confounding the relation between diet and ENL in serum or urine
may have drastic effects on the specificity of ENL as a biological marker of dietary
exposure. However, little is known about these non-dietary determinants. Oral
antimicrobial treatment, as a result of the destruction of colon microflora, di-
minishes ENL formation in the gut. In a recent cross-sectional study of Finnish
subjects, the strong association between serum ENL and dietary MAT and SEC
intake disappears in users of antimicrobials (Kilkkinen et al. 2003a). In the same
study population, oral antimicrobial treatment decreased serum ENL concentra-
tion for up to 12-16 months, and the fall in the concentrations was stronger after
several treatments (Kilkkinen et al. 2002). By contrast, in an American multi-
ethnic population, the intake of antibiotics during the preceding year had not
influenced ENL urinary excretion. No information was, however, available on
the recency of the intake (Horn-Ross et al. 1997). Another study showed highly
elevated serum ENL concentrations in patients with severe diabetic nephropathy,
which supports the important role of kidney function in elimination of ENL.
Whether related to kidney function or not, age seems to be positively associated
with ENL (Horner et al. 2002). In addition, a high body mass index (BMI)
30
Table 5. Reported determinants of serum/plasma and urine ENL1
Reference Subjects Diet n Dietary
assessment
Adlercreutz et al. 1981 American F omnivore 12 food record
vegetarian 14
Adlercreutz et al. 1986 American F omnivore 20 food record
vegetarian 20
omnivore 7
(breast cancer patients)
Adlercreutz et al. 1987 Finnish F habitual 48 food record
Adlercreutz et al. 1991 Japanese F+M habitual 19 food record
Lampe et al. 1999 American F+M low or high vegetable 98 5-d food record
Horner et al. 2002 American F+M low or high vegetable 203 3-d food record
Hulten et al. 2002 Swedish F habitual 740
Vanharanta et al. 2002 Finnish M habitual 100 4-d food record
Kilkkinen et al. 2003 Finnish M habitual 428
Vanharanta et al. 2003 Finnish M habitual 1889 4-d food record
von Hertzen et al. 2004 Finnish type 1 habitual 400
1 Abbreviations: ENL, enterolactone; F, female; M, male; pos, positive; neg, negative; n.a., no association; FFQ,
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Statistical method Measurement Determinant Association % of Variance
explained
correlation ENL 72-h urine excretion fiber pos (r=0.59)
correlation between ENL 72-h urine excretion grain intake pos (r=0.996)
means of the groups in four samples
Pearson correlation ENL 72-h urine excretion vegetable fiber pos (r=0.32)
(effect of body weight in four samples berries and fruit fiber pos (r=0.51)
and age eliminated) legume fiber pos (r=0.31)
total fiber pos (r=0.53)
Pearson correlation ENL 48-h urine excretion green and yellow vegetables pos (r=0.53)
boiled soybeans pos (r=0.76)
Pearson correlation ENL 72-h urine excretion vegetables n.a.
fruit pos (r=0.20)
fiber pos (r=0.24)
from vegetables n.a.
from fruit n.a.
from grains pos (r=0.22)
linear regression model Serum ENL fiber 22 %
water-soluble pos (r=0.35)
water-insoluble pos (r=0.34)
fruit n.a.
vegetables pos (r=0.17)
fat n.a.
caffeine pos (r=0.21)
alcohol pos (r=0.24)
age pos
female sex pos
BMI neg
comparison of medians Serum ENL smoking neg
linear regression model Serum ENL fiber 17 %
water soluble pos (r=0.39)
water insoluble pos (r=0.28)
fruit and berries pos (r=0.25)
vegetables pos (r=0.24)
cereals pos (r=0.19)
Spearman correlation Serum ENL age pos
smoking neg
number of smoking years pos (in control group)
BMI neg (in prostate cancer cases)
linear regression model Serum ENL fiber pos 10 %
vegetables pos
alcohol neg
saturated fatty acids neg
constipation pos
BMI neg
number of bronchitis neg
analysis of variance Serum ENL severity of renal disease pos
Pearson correlation serum creatinine pos (r=0.60)
systolic blood pressure pos (r=0.24)
ENL 24-h urine excretion severity of renal disease n.a.
food frequency questionnaire
}
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appears to be associated with low serum ENL concentration (Horner et al. 2002,
Hulten et al. 2002, Vanharanta et al. 2003). Caffeine intake showed a strong
positive correlation with plasma ENL concentration (Horner et al. 2002). The
results on the effect of alcohol are conflicting; the association has been both
positive (Horner et al. 2002) and negative (Vanharanta et al. 2003). Some early,
small-scale studies suggested that ENL follows a cyclic pattern of excretion
during the menstrual cycle (Setchell et al. 1979, 1980a, 1980b, Stitch et al.
1980). A later study with 18 women consuming flaxseed for three menstrual
cycles found no differences in ENL or END excretions in three-day urine samples
from follicular and luteal phases (Lampe et al. 1994).
Intervention studies
A number of studies have demonstrated an increase of serum or plasma ENL
concentration in human subjects after supplementation of diet with flaxseed
(Morton et al. 1994, 1997a, Nesbitt et al. 1999, Tarpila et al. 2002). In
addition, incorporating strawberries (Mazur et al. 2000), rye bran bread (Bylund
et al. 2003), or whole-grain products (Jacobs et al. 2002) into a controlled,
low-lignan basal diet raised serum ENL concentrations. Similar changes were
present in urinary ENL excretion in several intervention studies. For a review,
please refer to the thesis by Niina Saarinen (2002b).
In a recent intervention study, a high-fiber rye diet raised serum ENL
concentrations, whereas with a high-fiber wheat diet the concentrations remained
unchanged compared with a low-fiber basal diet (McIntosh et al. 2003). Substitu-
tion of rye flour with phloem (pettu) powder effectively increased serum ENL
concentration (Vanharanta et al. 2002a). Not all studies have indicated positive
results; supplementation of a fiber-free diet with whole-grain rye bread for 12
volunteers had no impact on serum ENL concentration (Pool-Zobel et al. 2000).
In another intervention in Finnish subjects, surprisingly, supplementation of the
habitual diet with rye bread caused no changes in serum or urine ENL levels,
although the intake of rye doubled. The authors suggested a plateau with intakes
of 70-90 g rye bread/day, resulting in mean serum ENL concentrations of 26
nmol/L in men and 40 nmol/L in women. No dose-response correlation was
present between rye bread intake and ENL in serum or urine (Juntunen et al.
2000). A common feature of all of the intervention studies was the notable
between-subject differences in ENL production.
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Enterolactone in breast cancer
Epidemiological studies
Enterolactone in body fluids and breast cancer risk
Case-control studies
Already in 1982, the first descriptive study suggested that ENL may protect against
breast cancer. The mean urinary excretion of ENL in four 72-h urine collections
was lower in 7 women with breast cancer than in 10 vegetarian and 10 omnivo-
rous healthy women (Adlercreutz et al. 1982). Subsequent case-control studies
have supported this finding. In an Australian study with 144 pairs, 72-h urinary
excretion of ENL had an inverse association with risk of breast cancer. The odds
ratio (OR) in the highest quintile of ENL excretion was 0.36 (95% confidence
interval (CI) 0.15-0.86) after adjustments for age at menarche and alcohol and
total fat intakes (Ingram et al. 1997). Similarly, urinary ENL:creatinine ratio was
inversely associated with breast cancer risk in 250 Chinese breast cancer patients
with individually matched controls. The OR in the highest tertile was 0.42 (95%
CI 0.25-0.69) after adjustment for age, age at first live birth, a diagnosed
fibroadenoma, total meat intake, and physical activity level (Dai et al. 2002). The
authors, later, reanalyzed a subgroup of 117 pairs and found a stronger inverse
association of urinary lignans with breast cancer among women with a high BMI
or waist:hip ratio. However, no association existed after stratifying by plasma
steroid or SHBG concentration (Dai et al. 2003).
Prospective studies
To date, only four prospective studies on serum or urine ENL and breast cancer
risk are available. A recent follow-up study suggested that ENL has a strong
protective effect on the breast cancer risk. It assessed the relationship between
serum ENL concentrations and the occurrence of breast cancer in 383 Italian
women with palpable cysts. After a median follow-up of 6.5 years, 18 women had
developed invasive breast cancer. Median serum ENL concentrations were lower
in women with breast cancer than in controls: 8.5 nmol/L versus 16 nmol/L.
The OR in the lowest quintile (Serum ENL ≤8 nmol/L) was 0.36 (95% CI 0.14-
0.93) (Boccardo et al. 2004). A nested case-control study with 248 Swedish cases
and 492 controls from three cohorts showed an increased risk of breast cancer in
women below the 12.5th percentile (mean plasma ENL 2.9 nmol/L) and,
surprisingly, in two of the cohorts above the 87.5th percentile (mean plasma ENL
58 nmol/L). The authors suggested that this discrepancy may derive from pure
chance, excessive intake of flaxseed, disturbed hormonal metabolism, or the
effect of alcohol on ENL levels (Hulten et al. 2002). The other two nested case-
control studies demonstrated negative results; serum ENL concentration was not
associated with risk of breast cancer in a Finnish study with 206 women with
breast cancer (both pre- and postmenopausal) and 215 controls (Kilkkinen et al.
34
2004), nor did a Dutch study with 88 postmenopausal breast cancer cases and
268 controls find any association between overnight urinary ENL:creatinine
ratio and breast cancer risk (den Tonkelaar et al. 2001).
A recent, interesting follow-up study showed that ENL accumulates in breast
cysts (Boccardo et al. 2003). The study included 191 women, 12 of whom
developed breast carcinoma during the follow-up. Intracystic ENL did not
correlate with breast cancer risk. However, it modulated the effect of intracystic
EGF concentration, which is a strong predictor of breast cancer. ENL appeared
to decrease the cancer risk of patients with high intracystic EGF concentration,
while in patients with low intracystic EGF concentration ENL increased the breast
cancer risk.
Dietary lignans and breast cancer risk
A case-control study with 207 women with breast cancer and 188 controls showed
a reduced breast cancer risk in women in the highest tertile of dietary lignan
intake. The ORs in the highest tertile were 0.45 for premenopausal (95% CI
0.20-1.01) and 0.59 (0.28-1.27) for postmenopausal women. The risk
reduction was substantially higher in premenopausal women with at least one A2
allele of the cytochrome P450c17α gene leading to high estrogen levels (OR
0.12, 95% CI 0.03-0.50) (McCann et al. 2002). The opposite findings were
observed in the second American case-control study with 1326 cases and 1657
controls, in which the intake of MAT and SEC was not associated with breast
cancer risk (Horn-Ross et al. 2001). Similarly, two cohort studies, one with
111 526 Californian (Horn-Ross et al. 2002) and the other with 15 555 Dutch
(Keinan-Boker et al. 2004) women, found no association between dietary lignan
intake and breast cancer risk.
Dietary lignan intake may not be a suitable marker of body exposure to
mammalian lignans because this measurement is unable to take into account the
large between-subject differences in the intestinal conversion of plant precursors
to mammalian lignans. In addition, there is insufficient knowledge occurrence of
lignans in common foods, leading to an underestimation of plant lignan intake.
Thus, the relevance of these studies in elucidating the role of ENL in preventing
breast cancer is uncertain.
Experimental studies
In vitro
The in vitro evidence of (anti)estrogenity of ENL is summarized above. ENL was
able to inhibit various steps of metastasis in two estrogen receptor-negative
human breast cancer cell lines. At concentrations of 1-5 µM, the inhibition of
cell adhesion and invasion was dose-dependant. When ENL, END, and tamoxifen
were combined in a 1 µM dose, a greater inhibitory effect on cell adhesion and
invasion was observed than with any of these compounds alone. ENL at doses of
0.1-10 µM reduced cell migration (Chen et al. 2003b). ENL may have an
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antiproliferative effect on estrogen receptor-negative breast cancer cells (Hirano
et al. 1990, Wang et al. 1997), but only at such high concentrations that the
relevance of this finding is questionable.
In vivo
Animal studies
Experimental animal studies provide strong evidence of a beneficial action of
lignans against mammary carcinoma at several stages. Orally administered ENL
(Saarinen et al. 2002a), HMR (Saarinen et al. 2000, 2001), flaxseed (high in
SEC diglycoside), or SEC diglycoside (Thompson et al. 1996a, 1996b)
suppressed the growth of chemically (7,12-dimethylbenzanthracene, DMBA)
induced mammary tumors. ENL and HMR were additionally shown to increase
the proportion of stabilized and regressing tumors (Saarinen, et al. 2001, 2002a).
The growth inhibition was observed when serum lignan concentrations were
hundreds of nanomols. Flaxseed, by contrast, was less protective against N-methyl-
N-nitrosourea (NMU) -induced mammary tumorigenesis in rats, and low doses
even suggested tumor promotion. The authors considered the disparities to be
related to differences in experimental design, different carcinogen, and protective
effects of the alpha-linolenic acid present in the basal diet (Rickard et al. 1999).
In a nude mice model, flaxseed reduced by 45% the incidence of metastasis in
established estrogen receptor-negative human breast cancers (Chen et al. 2002).
The authors stated that this effect was partly due to downregulation of IGF-I
and EGF receptor expression. Developmental studies showed that exposure of
rat pups to lignans during suckling enhances the differentiation of developing
mammary gland structures (Ward et al. 2000), which subsequently suppresses
DMBA-induced mammary tumorigenesis (Chen et al. 2003a).
Human studies
Experimental studies in women on the effect of lignans on breast cancer develop-
ment are sparse. One randomized, double-blind, placebo-controlled study deter-
mined the effect of daily consumption of a placebo muffin versus a muffin
containing 25 g of flaxseed from the time of diagnosis to the time of surgery.
Analysis of tumor tissues indicated reduced tumor growth in the flaxseed group
(Thompson et al. 2001).
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Aims of the study
This study aimed to:
1. Develop a TR-FIA methodology for serum ENL
Specific aims were to:
a. elucidate the etiology for the differing results of the original and revised
versions of the basic TR-FIA for serum ENL
b. validate the revised version of the basic method
c. develop a fully automated short method for serum ENL measurement
2. Study the characteristics of ENL as a biological marker
In this part of work, specific aims were to investigate:
a. the reliabilities of serum and urine ENL measurements
b. the associations between ENL concentrations in serum and urine
c. the serum concentrations of ENL in the Finnish population
d. the determinants of serum ENL concentration
e. whether serum ENL levels can be modified by diet at the population level
3. Investigate whether serum ENL is related to breast cancer risk in Finnish
women
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Materials and methods
Materials
Instrumentation
TR-FIA
The time-resolved fluoroimmunoassay for ENL was performed with the following
equipment:
1. A VICTOR 1420 multilabel counter with software version 1.0 for
fluorescence measurements, and a dissociation-enhanced lanthadine fluoro-
immunoassay (DELFIA) plate washer and plate shaker (Wallac Oy, Turku,
Finland) for immunoassay procedures (I, III, IV, V).
2. An AutoDELFIA 1235 Automatic Immunoassay System (Wallac Oy, Turku,
Finland) (II).
Radioactivity counting
An LKB 1217 Rackbeta scintillation counter was used to calculate radioactivity
(β-radiation) for recovery calculations.
GC-MS
Isotope dilution gas chromatography-mass spectrometry in the selected ion
monitoring mode with synthesized deuterated internal standard was used as a
reference method. The GC-MS instrument was a Fisons MD 1000 quadruple
mass spectrometer combined with a Fisons GC 8000 gas chromatograph.
Helium was used as the carrier gas.
HPLC-CEAD
The high-performance liquid chromatography system consists of two Model 580
ESA (ESA Inc., Chelmsford, MA, USA) solvent pumps, a Model 540 ESA au-
tosampler with refrigeration, a thermal chamber for a column, and a detector,
two detector cells each containing four measuring electrode pairs, a system
control module, and a computer.
DCA 2000 analyzer
Urinary creatinine concentrations were determined using a DCA 2000 Analyzer
(Bayer, Elkhart, IN, USA).
Statistical equipment
The statistical analyses were performed using SPSS package program version 9.0
(IV) or 10.0 (II) (SPSS Inc., Chicago, IL, USA) and SAS program Ver 6.12 (SAS
Institute Inc., Cary, NC, USA) (III).
38
Standards, chemicals, and reagents
Standards
ENL, END, MAT, SEC (Bannwart et al. 1984, Adlercreutz et al. 1986b), ENL
hydroxylation metabolites (Mäkelä et al. 2000, 2001), and 5-O-carboxymeth-
oxy-ENL (Adlercreutz et al. 1998) were synthesized and PIN (Nishibe et al.
1990) was isolated as described.
Immunogen synthesis and immunization
The 5-O-carboxymethoxy-ENL was coupled to bovine serum albumin (BSA),
and the conjugates were used for the immunization of rabbits. Immunogen
synthesis and immunization have been described in detail elsewhere (Adlercreutz
et al. 1998).
Fluorescence label
A Europium chelate of 5-O-carboxymethoxy-ENL served as the fluorescence
label for TR-FIA (Adlercreutz et al. 1998).
Chemicals and reagents
Enzymes
β-glucuronidase (EC 3.2.1.31) (Boehringer-Mannheim, Mannheim, Germany;
Cat. No. 1585665)
Sulfatase (EC 3.1.6.1) (Sigma, St. Louis, MO, USA; Cat. No. S9626)
Reagents
BSA, diethyl ether, methanol, ethanol (Merck AG, Darmstadt, Germany)
[6,7-3H]Estradiol-17β-glucuronide (NET 1106, 250 µCi (9.25 MBq)) (NEN
Lifescience Products)
Goat anti-rabbit IgG-coated microtitration strips (Wallac Oy, Turku, Finland)
DELFIA enhancement solution (Wallac Oy, Turku, Finland)
DELFIA wash concentrate (Wallac Oy, Turku, Finland)
Buffers
Hydrolysis buffer: 0.1 M acetate buffer, pH 5
Assay buffer: 50 mM Tris-BSA buffer, pH 7.8 containing 8.78 g of NaCl, 0.5 g
of sodium azide, 5 g of BSA, and 0.1 g of Tween 40 per liter
Glassware
The samples were handled in disposable glass tubes (12 × 75 mm).
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Human samples
Ethics
The study protocols were approved by the Ethics Committees of the hospital
district of Helsinki and Uusimaa (II), the National Public Health Institute (III,
IV), and the University of Kuopio (V).
Study II
Subjects
Twenty volunteers recruited among university students gave their written
consent before entering the study. Exclusion criteria were age less than 18 years,
antibacterial treatment during the preceding 3 months, any major illness, and
any regular medication, except contraceptive pills. One female subject who regu-
larly took an antidepressant reported this only at the end of the study. One
subject dropped out because of antibacterial treatment for a urinary infection.
One spot urine sample was missing for a female subject; this participant was
subsequently excluded from that analysis.
Study design
The serum, spot urine, and 24-h urine samples were collected on 5 successive
days (Monday to Friday, within-week variation) and on the following 3 Mondays
(within-month variation).
Study III
Subjects
The participants of the national cross-sectional survey were 25-64 years old and
lived in 5 areas: 1) Helsinki and Vantaa (the metropolitan area), 2) the cities of
Turku and Loimaa as well as some rural communities in Loimaa, and the
provinces of 3) North Karelia, 4) Kuopio, and 5) Oulu. An independent random
sample (n=10 000) stratified by 10-year age groups, regions, and sex, was drawn
from the National Population Register. For the dietary survey subsample, 4000
of these individuals were chosen and 72% subsequently participated. Subjects
who had used antibiotics within the past 3 months (n=372) were excluded.
Study design
The venous samples were taken from the subjects at the clinical examination.
Data on health, socioeconomic factors, physical status, smoking, alcohol
consumption, and dietary habits were collected by a self-administered question-
naire. A food frequency questionnaire (FFQ) including 38 food items was used
to assess dietary intake over the previous 12 months. The consumption of whole-
grain products was quantified by summing up the consumption of rye bread,
crisp bread, porridge, and cereals. Consumption of vegetables was calculated by
summing up the consumption of salad vegetables, roots, legumes, vegetable dishes,
and consumption of fruit and berries by summing up the consumption of fruit,
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berries, and juices. For the analyses, subjects were divided into tertiles by frequen-
cy of consumption of whole-grain products, vegetables, and fruit and berries.
Studies IV and I
Subjects
The intervention study was carried out in two semi-rural communities (Kitee and
Tohmajärvi) in North Karelia, Finland, in spring 1983. The original aim of the
study was to investigate the effects of dietary modification on blood pressure and
serum lipids (Kuusi et al. 1985, Puska et al. 1985). The participating families
had been initially identified through the countrywide hypertension register or
through local risk factor screenings. Persons aged 35-49 years with known
borderline or mild hypertension and no antihypertensive treatment, as well as
their spouses, were invited to participate. The volunteers gave their written
informed consent, and, if no exclusion factors emerged, underwent a medical
examination. One person with major health problems was excluded during the
study, and the final study group comprised 85 middle-aged subjects.
Study design
The study consisted of a baseline period of 2 weeks, a 12-week intervention
period, and a 5-week switchback period. A fasting venous blood sample was
taken at the end of each period and in the middle of the intervention period
(Kuusi et al. 1985, Puska et al. 1985).
During the baseline and switchback periods the families ate their usual diets.
The local North Karelian diet has traditionally been high in saturated fat derived
from whole-milk products and meat, and low in polyunsaturated fat and
vegetables. During the intervention the subjects were given counseling to reduce
the intake of fat and increase the consumption of grain products as a carbo-
hydrate source, as well as vegetables, berries, and fruit. The families were randomly
allocated into two groups with different polyunsaturated/saturated fatty acid
ratios by providing the families with different fat spreads. The subjects kept a
food consumption record for 7 days during the baseline, 12 days during the
intervention, and 10 days during the switchback period. The study protocol
concerning changes in foods was identical to an earlier study in the same area
(Pietinen et al. 1984). The consumption of dairy products, cereal products, meat,
and eggs did not change significantly, while the consumption of vegetables, fruit
and berries, fish, and low-fat cheese increased.
Study V
Subjects
The subjects were participants in the Kuopio Breast Cancer Study. During the
period from April 1990 to December 1995, all women living in the catchment
area of Kuopio University Hospital who had breast symptoms or suspected a
lump were referred for further examination and interview by a local physician.
The age range of subjects was 25-75 years. Of women entering the hospital for
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breast examination, only 3% refused to participate in the study. Of all partici-
pants, 24% were later diagnosed with breast cancer. A random sample of popula-
tion controls was drawn from the National Population Register covering the
same geographical area. The controls were matched to breast cancer cases by age
(within ±5 years) and area of residence (rural/urban). The participation rate of
the population controls was 72%. For ENL analyses, a subset of cases and
controls was selected, covering the time period 1992-1995. After exclusions
because of missing data, 194 cases and 208 controls were available for analysis.
Data collection
In cases, the venous blood sample was drawn before undergoing the hospital
examinations for diagnosis. The study nurse interviewed the women with
questionnaires on demographic, reproductive, and lifestyle characteristics, and
guided the anthropometric measurements. The controls visited the hospital to
give a blood sample and an interview. The diet over the preceding 12 months was
assessed by a semiquantitive FFQ (Männistö et al. 1999).
Sample preparation
All venous samples were drawn after at leat 4 h of fasting. The serum aliquots
used had been thawed either once (V, I+IV partly) or stored unthawed (II, III)
until the analysis of ENL. Collection of the 24-h urine samples (II) began 24 h
prior to the serum samples being drawn. They were collected in 2-L plastic con-
tainers containing 2 g of ascorbic acid. After the collection, the volumes of the
24-h urine samples were measured. Spot urine samples were collected at the end
of each 24-h collection.
Methods
Analytical methods
TR-FIA for serum and urine enterolactone
Basic method for serum enterolactone (I, II, IV, V)
Pretreatment. First, 25 µg of 3H-estradiol glucuronide was added to 250 µL of
serum sample. The sample was hydrolyzed overnight with 250 µL of hydrolysis
reagent containing hydrolysis buffer with 0.2 units/mL β-glucuronidase and 2
units/mL sulfatase. After hydrolysis, the serum samples were extracted twice with
diethyl ether. After extraction and evaporation, 250 µL of assay buffer was added
to the tubes to obtain the original sample volume. The recovery of the hydrolysis
and extraction steps was measured by radioactivity counting.
Enterolactone measurement. Twenty microliters of sample, 100 mL of assay
buffer with antiserum, and 100 µL of assay buffer with the europium label were
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pipetted in duplicate on antirabbit microtitration strips. The plates were incu-
bated slowly on a plate shaker for 90 min, after which the strips were washed and
shaken further with enhancement solution for 5 min, and then the fluorescence
was measured.
Calculations. The final results were obtained by correcting the measured
concentration for the average recovery of the samples.
Short method for serum enterolactone (I, III)
Pretreatment. Fifty microliters of serum samples were incubated with 50 µL of
hydrolysis reagent containing sulfatase and β-glucuronidase overnight at 37°C.
After hydrolysis, 150 µL of assay buffer was added to the samples.
Enterolactone measurement was performed equally as described for the basic
method.
Calculations. To obtain results corresponding to the basic method, the final
results were calculated according to the formula:
Final concentration = [measured concentration] × 0.934–11.03
TR-FIA for urine enterolactone (II)
Pretreatment. Fifty microliters of urine was hydrolyzed overnight with 450 µL of
the same hydrolysis reagent as in serum ENL assay. After hydrolysis, the urine
samples were diluted further with the assay buffer to obtain optimal pH and
protein and analyte concentrations for the assay (Uehara et al. 2000b).
Enterolactone measurement was performed as for serum ENL measurements.
Calculations. The final results were calculated as follows:
Final concentration = [measured concentration] × 10 × dilution factor.
Quality control
The measurement was repeated if the results of the duplicate fluorescence
measurements deviated more than ±15% from the mean value and 1.0 nmol/L
from each other. The urine samples were diluted further with the assay buffer
when the sample concentrations exceeded 100 nmol/L to reach the linear part of
the standard curve.
The batches of serum samples included two (IV, V) or three (II, III) quality
control samples with different ENL concentrations repeated once in every 40
samples. The urine samples (V) were analyzed with two urine quality control
samples. The control samples were pooled serum samples either obtained from
the Finnish Red Cross or collected from laboratory personnel.
Urine creatinine (II)
Urinary creatinine concentrations were determined by a colorimetric method with
a modified Benedict-Behre reaction. The method is based on the reaction of 3,5-
dinitrobenzoic acid with creatinine in a highly alkaline medium. Validation of
the method has been presented elsewhere (Hiar 1997).
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GC-MS (I)
GC-MS for plasma ENL was used as a reference method. The original method
(Adlercreutz et al. 1993b) was slightly modified as described earlier (Adlercreutz
et al. 1998).
HPLC-CEAD (I)
Study I measured ENL in serum after incubation of samples with varying enzyme
amounts. The samples were otherwise pretreated as described above for basic TR-
FIA for serum ENL. ENL measurements were performed by both TR-FIA and
HPLC-CEAD. The chromatographic conditions were described in detail by Nurmi
et al (1999).
Statistical methods
Intra- and inter-assay coefficients of variation (CV) were calculated as follows:
CV= σ/average. The limit of detection in analysis was determined according to
the definition by the International Union of Pure and Applied Chemistry (IUPAC)
(limit of detection = 3(standard deviation of the blank) + signal from the blank)
(McNaught et al. 1997).
ENL concentrations are expressed as median values ±95% CI or range. All
calculations for statistical significance were performed on a logarithmic scale to
obtain a normal distribution. The findings were considered significant at p<0.05.
The reliability calculations (II) included ICC, between-subject variance (σ2B),
within-subject variance (σ2W), analytical variance (σ
2
A), and total variance. σ
2
A was
obtained by measuring the day-one samples in two aliquots. Individual variances
(σ2I) were calculated by the following formula: σ
2
I = σ
2
W - σ
2
A. The reliabilities
within a week (five consecutive days) and within a month (four consecutive Mon-
days) were estimated separately. Standard deviations (σ) were estimated as square
roots of the respective variances, and CVs were calculated by the following for-
mula: CV = 100(eσ-1) % (Bland et al. 1996). The number of repeated measure-
ments (of samples collected in different weeks) needed to estimate the underlying
homeostatic set point to within ± 50% with 80% confidence was calculated by the
formula presented by Fraser and Harris (1989).
Pearson correlation coefficients with 95% CIs were calculated between ENL
levels in urine and serum samples from the same person (Hopkins 2002). The
serum:urine ENL ratios were also calculated separately for each person, and
possible differences between subjects were tested by one-way ANOVA, Tanhame‘s
test (not assuming equal variances) as a post hoc test to determine which
individuals differed from each other.
The determinants of serum ENL concentration (III) were identified by a
regression model. All variables (age, education, BMI, constipation, self-reported
physical health, smoking, and consumption of alcohol, whole-grain products,
vegetables, and fruit and berries) were examined as potential determinants of
serum ENL concentration. In the final model, only the significant variables were
included. The analyses were done separately for men and women.
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The differences in median concentrations in Study IV were tested by repeated
measures ANOVA with least significant difference as a post hoc test.
The association between serum ENL and risk of breast cancer (V) was
determined with a logistic regression model. Group matching of cases and
controls was used, and the quintiles were based on cases and controls combined.
The regression model was adjusted for age, area, age at menarche and at first
full-term pregnancy, first-degree family history of breast cancer, history of benign
breast disease, education, current alcohol intake, smoking, leisure time physical
activity, waist-to-hip ratio, and BMI. Data were analyzed separately for premeno-
pausal and  postmenopausal  women. The  effect  of  short-term  variation  in
serum ENL concentrations on the odds ratio was calculated by the following
equation: ORobserved = e
(lnORtrue × ICC) (White 1997).
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Results
TR-FIA for serum enterolactone
Differences in serum enterolactone results (I)
This study compared for the first time the results of the original and the revised
versions of the basic TR-FIA with each other and with the GC-MS reference meth-
od. Unexpectedly, a striking discrepancy was present in these results (Fig. 3).
Fig. 3. Linear correlations between S-ENL concentrations measured by GC-MS and a) the
original and b) the revised versions of basic TR-FIA for serum ENL.
The analysis of 184 serum samples showed that the results of the two versions of
TR-FIA associated rather poorly with each other. If reanalysis of the samples is
impossible, the results of the original version of the basic method can be
corrected by the following formula:
[result of the revised basic version] = 0.63 × [result of the original version] – 6.8
R=0.60, p<0.001, n=184.
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Explaining the differences in study results
Effect of enzymes (I)
Both versions of the method use a partially purified sulfatase manufactured from
the snail Helix Pomatia (also with β-glucuronidase activity), and a specific β-
glucuronidase produced in bacteria. Whether one or both of these enzymes caused
the difference in the results was tested by changing the enzyme amounts one at a
time.
β-glucuronidase
Hydrolysis of the glucuronides proved to be sufficient with the smaller amount
of β-glucuronidase present in the revised version of the basic method (0.2 U/
mL). Its increase did not change the results (Fig. 4).
Sulfatase
Increase in the amounts of sulfatase used in hydrolysis caused dramatic changes in
the results. TR-FIA measured linearly increasing ENL concentrations when the
Fig. 4. Hydrolysis of serum (200 µL) with hydrolysis reagent (200 µL) with different
β-glucuronidase [(EC 3.2.1.31, Cat. No. 1585665) from Boehringer-Mannheim]
concentrations. ENL concentrations were measured by TR-FIA.
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concentrations of sulfatase in the hydrolysis reagent rose (Fig. 5). HPLC-CEAD,
by contrast, detected no differences between the samples. The results were similar
when the amount of sulfatase was raised by increasing the amount of the
hydrolysis reagent per sample. The results of TR-FIA and HPLC-CEAD were
closest to each other with the sulfatase amount present in the revised version of
the basic assay (200 µL hydrolysis reagent with sulfatase 2 U/mL).
Fig. 5. Hydrolysis of serum (200 µL) with hydrolysis reagent (200 µL) with different
sulfatase [(EC 3.1.6.1, Cat. No. S926) from Sigma] concentrations. ENL concentrations
were measured by TR-FIA and HPLC-CEAD.
Effect of matrix (I)
With its strong brown color, sulfatase might itself cause fluorescence. This was,
however, not the case; the enzyme alone caused no changes in fluorescence when
hydrolysis was performed in buffer or ENL standard solution, or in serum with-
out incubation. This led to the hypothesis that sulfatase disturbs the assay by
releasing some compound(s) from the matrix.
Cross-reactions of antiserum
Compound(s) responsible for the disturbance of the assay may structurally
be related to ENL. They may be liberated from plasma during hydrolysis and
bind to the antiserum, and thus interfering with the results. ENL has several
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structurally closely related metabolites. Unfortunately, not all of them were
available as standards. Of the tested compounds, α-,β-desmethyl-β-deshydroxy
MAT exhibited a significant cross-reactivity. The results from the cross-reactions
of the related, available compounds are presented in Table 6.
Table 6. Cross-reactions of the antiserum and the structures of the 5-O-
carboxymethoxy-ENL and the MAT derivatives.
Compound Cross-reactivity
1. Present in large amounts in circulation
daidzein –
genistein –
equol –
quercetin –
enterodiol 0.2%
2. Present in trace amounts or not present in circulation
secoisolariciresinol –
matairesinol –
pinoresinol –
lariciresinol –
isolariciresinol –
7’-OH-enterolactone1 0.7%
α-desmethyl-β-desmethoxy matairesinola2 –
bis-desmethoxy matairesinola3 –
bis-(desmethyl) matairesinola4 ~0.1%
α-,β-desmethyl-β-deshydroxy matairesinola5 ~10%
1-5Structures presented below (1-5)
aNo quantitative standard solution available, cross-reactivity is only estimated
References: Stumpf K. et al. unpublished results, Adlercreutz et al. 1998
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Fig. 6. Correlation between the short and the basic TR-FIA for serum ENL.
Short TR-FIA for serum enterolactone (I)
Development of the short TR-FIA aimed at an automated method for auto-
DELFIA. Because only a minor portion of circulating ENL is in free form, its
direct measurement in serum without any sample pretreatments failed to yield
reliable results. Therefore, the second stage was to inspect an assay with
hydrolysis but no extraction. Inclusion of hydrolysis freed all of the ENL
conjugates for measurement, while exclusion of extraction eliminated the
manual part of the method. Exclusion of extraction resulted in a higher mean
serum ENL concentration (45 nmol/L) than the basic TR-FIA for serum ENL
(29 nmol/L) or the GC-MS (28 nmol/L). Even so, the correlation between
these methods was excellent (Fig. 6). The short method turned out to be useful,
but the final results require a mathematical conversion by using the following
equation:
[basic TR-FIA] = 0.87 × [short TR-FIA] – 11.3
r=0.94, p<0.001, n=262
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Validation of the method
Precision
The intra- and inter-assay CVs for the basic and the short TR-FIA are presented
in Table 7.
Table 7. Intra- and inter-assay coefficients of variation (CV) for serum ENL
by the basic (a) and short (b) TR-FIA.
 a.                        b.
Concentration Number of CV (%) Concentration Number of CV (%)
(nmol/L) samples (nmol/L) samples
Intra-assay Intra-assay
13.2 10  4.7 30.7 10 4.0
38.0 10 6.0 58.5 10 6.1
79.5 10 3.3 106.7 10 3.1
Inter-assay Inter-assay
16.3 20 9.0 3.7 20 7.0
45.2 20 9.9 14.1 20 6.1
96.6 20 6.9 59.5 20 8.6
Comparisons with the reference method
The residual plots between the reference method GC-MS and the basic and the
short TR-FIA for serum ENL are presented in Fig. 7.
Fig. 7. Residual plots between a) GC-MS and the basic TR-FIA for serum ENL, and
b) GC-MS and the short TR-FIA for serum ENL.
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Sensitivity
Detection limit
Detection limit, expressed as the minimal amount of ENL distinguishable from
the zero sample with 95% probability is 0.35 nmol/L.
Working range
Studies I and III-V used a standard curve with a working range of 1.5-540 nmol/
L (Fig. 8, standard curve 1). The working range in the basic and the short
method was identical. Because the distribution of serum ENL concentrations in
the Finnish population was shown to be skewed toward zero (III), there was a
need to widen the working range towards the low concentrations. Therefore, a
more sensitive standard curve with a working range of 0.4-300 nmol/L (Fig. 8,
standard curve 2) was developed and taken into use in Study II.
Fig. 8. The standard curves. The lines connect the lowest and highest points of the working
range.
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Serum enterolactone as a biological marker
Serum enterolactone concentrations in the Finnish population
(II-V)
The median concentrations were 7.3 (range 0.4-25.7) (II), 15.3 (0-183) (III),
12.2 (1.1-71.9) (IV), and 19.3 (0.5-124) (V) nmol/L. The distribution of
serum ENL was highly skewed and concentrated in the low values. Serum ENL
concentrations were higher in women than in men and in older than in younger
subjects (III).
Reliability of enterolactone measurements (II)
The ranges and median ENL concentrations of the eight samples collected from
each subject are presented in Fig. 9. The median ENL serum concentration and
urinary excretions, as well as the ICCs and the numbers of samples required to
estimate the underlying homeostatic set point, are presented in Table 8.
Table 8. Overall median concentrations, intra-class correlation coefficients,
and number of samples (on different weeks) required to estimate the underlying
homeostatic set point.
Spot urine
Serum ENLa 24-h urine ENL ENL:creatinine
nb 19 19 18
Overall median 9.1 nmol/L 2460 nmol/24 h 289 µmol/mol
Intra-class correlation
coefficient (95% CIc)
within-week 0.79 (0.65-0.90) 0.80 (0.67-0.91) 0.72 (0.55-0.86)
within-month 0.77 (0.61-0.89) 0.79 (0.64-0.90) 0.67 (0.46-0.84)
Number of samples
required to estimate the
underlying homeostatic
set point, within-monthd 3 3 10
a enterolactone
b number of subjects included in analysis
c 95% confidence interval
d to within ±50% with 80% confidence
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Fig. 9. Within-subject variations in (a) ENL serum concentration, (b) ENL urinary excretion, and (c) spot urine ENL:creatinine ratio. Lines indicate
the ranges and vertical bars the median concentrations of eight samples collected in one month.
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Association between enterolactone concentrations in serum and
urine (II)
Linear correlations existed between ENL measurements in serum, 24-h urine,
and spot urine (Fig. 10).
Determinants of serum enterolactone (III)
In men, multiple regression analysis showed a strong positive and independent
association between serum ENL and consumption of whole-grain products
(p=0.02) and fruit and berries (p=0.03), and constipation (p=0.02). Significant
Fig. 10. Correlations between (a) serum ENL concentration and 24-h urinary excretion,
(b) 24-h urinary excretion and spot urine ENL:creatinine ratio, and (c) serum ENL
concentration and spot urine ENL:creatinine ratio. Correlations were calculated between
single samples (day 1). ENL serum concentration relative to urinary excretion of one subject
(ƒ) deviates from the 15 others (p<0.05).
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positive associations between serum ENL and years of education and age were
also observed, but the associations did not remain significant after adjusting for
other variables. Similarly, despite nonsmokers and ex-smokers having over 25%
higher serum ENL concentrations than smokers, the association failed to remain
significant after adjusting for other variables. Vegetable consumption was not an
independent predictor of serum ENL, and no relationship was found between
serum ENL and BMI, physical status, or alcohol consumption. The final model
for men, including constipation and consumption of whole-grain products and
fruit and berries, explained only 2.7% of the variation in serum ENL.
In women, multiple regression analysis revealed that BMI (p=0.0001),
constipation (p=0.004), age (p=0.0003), and consumption of vegetables (p=0.0009)
were independently and positively associated, and smoking (p=0.0001) negative-
ly associated with serum ENL concentration. Other lignan-containing foods, as
well as self-reported physical status and education, were associated with serum
ENL; however, the associations did not remain significant after adjustment for
other variables. No association was observed between serum ENL and alcohol
consumption. Together, five variables (BMI, smoking, age, constipation, and
consumption of vegetables) in the final model for women explained almost 14%
of the variation in serum ENL.
Serum enterolactone in a dietary intervention study (IV)
The median concentration of serum ENL rose from 12.2 (95% CI 10.4-19.3)
nmol/L at baseline to 19.5 (16.1-31.5) nmol/L (p=0.002) during the
intervention period, being highest at the end of the intervention period. After
the 5-week switchback period, the concentrations had decreased only slightly, to
17.6 (95% CI 14.6-26.5) nmol/L (p=0.18). Serum ENL was <10 nmol/L in
33% of subjects during the baseline period and in as many as 24% of subjects at
the end of the intervention period. In 8% (7 subjects), serum ENL concentration
was <10 nmol/L in all four samples.
Enterolactone in breast cancer
The mean serum ENL concentration was 20 nmol/L for all cases and 26 nmol/
L for controls (p=0.003), 17 nmol/L for premenopausal cases and 21 nmol/L
for controls (p=0.10), and 21 nmol/L for postmenopausal cases and 29 nmol/
L for controls (p=0.01). The ORs adjusted for known risk factors for breast
cancer are presented in Table 9 (V). This table also shows the ORs without the
attenuating effect of within-subject variation in serum ENL (ICC=0.77).
Serum ENL was associated with intake of rye products, tea, dietary fiber (total
and water-insoluble), and vitamin E. No association was seen with vegetables,
fruit, or berries.
56 Table 9. Adjusted ORs of breast cancer in quintiles of serum ENL concentration, and the effect of the short-term
within-subject variation on the results (V).
Quintiles of serum ENL concentration P for trend
All women 1 2 3 4 5
S-ENL, nmol/L < 6.2 6.2–14.1 14.2–24.3 24.4–34.8 > 34.8
No. of cases 49 43 36 37 29
ORa (95% CI) 1.00 0.60 (0.30–1.17) 0.57 (0.29–1.13) 0.53 (0.27–1.05) 0.38 (0.18–0.77) 0.03
Premenopausal women
S-ENL, nmol/L < 5.5 5.5–11.4 11.7–20.2 20.6–30.0 > 30.0
No. of cases 17 14 13 13 11
ORa (95% CI) 1.00 0.82 (0.22–3.09) 0.39 (0.09–1.78) 0.52 (0.14–2.00) 0.42 (0.10–1.77) 0.18
Postmenopausal women
S-ENL, nmol/L < 6.3 6.3 - 14.9 15.1 - 26.0 26.1 - 37.7 > 37.7
No. of cases 32 29 23 24 18
ORa (95% CI) 1.00 1.19 (0.46–3.07) 0.60 (0.24–1.49) 0.80 (0.32–2.02) 0.50 (0.19–1.28) 0.10
aORs adjusted for age, area, age at menarche, age at first full-term pregnancy, use of oral contraceptives,
use of estrogen replacement therapy, first-degree family history of breast cancer, history of benign breast disease,
level of education, current alcohol intake, smoking habits, physical activity, waist:hip ratio, and BMI.
Effect of short-term variation (ICC=0.77) on the results, all women (additional analysis)
S-ENL, nmol/L < 6.2 6.2–14.1 14.2–24.3 24.4–34.8 > 34.8
ORobserved (95% CI) 1.00 0.60 (0.30–1.17) 0.57 (0.29–1.13) 0.53 (0.27–1.05) 0.38 (0.18–0.77)
ORtrue (95% CI) 1.00 0.52 (0.21–1.23) 0.48 (0.20–1.17) 0.44 (0.18–1.07) 0.28 (0.11–0.71)
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Discussion
Enterolactone as a biological marker
Both experimental and in vitro studies support the theory of the anticarcino-
genicity of lignans. Therefore, studying the characteristics of the most abundant
mammalian lignan, ENL, as a biological marker seemed justified.
Laboratory studies
The accuracy of the original version of basic TR-FIA for serum ENL was found
to be poor and a revised version of the method was described (I). The problems
had apparently originated from enzyme hydrolysis from too great a quantity of
sulfatase. The incubation of the matrix with the excessive enzyme led to a
disturbance of the assay. The revised version of the basic TR-FIA, by contrast,
proved to give reliable and repeatable results.
The exact mechanism for the interference remained unknown, and no other
groups have reported similar problems with hydrolysis. The antiserum for the
5-O-carboxymethoxy-ENL showed cross-reactions with some ENL metabolites
present in urine of human subjects. Could the cross-reactivity of lignan
metabolites with the ENL antiserum explain the problems in the methodology?
Probably not; although no data exist on the quantities of these metabolites in the
circulation, they are probably minimal in human subjects consuming their
habitual diet. A more likely explanation is that sulfatase releases some compound(s)
from the matrix. The compound(s) could act either by chelating the Europium
label or by binding to the antiserum. Nevertheless, the significance of the cross-
reactions of the lignan metabolites should be further studied when quantitative
standards of these compounds become available.
The TR-FIA for serum ENL is a feasible tool for epidemiological studies. The
advantages of TR-FIA in ENL analysis include its low costs, rapidness, and the
possibility of automation. Study III showed that the distribution of serum ENL
concentrations is skewed towards zero, which calls for sensitivity of the analytical
method. This is a major benefit of TR-FIA.
The short TR-FIA for serum without extraction reduces the costs of the method
even further. It is a useful alternative in large-scale studies or in studies with
limited sample quantity. The short TR-FIA gives higher results than the other
methods. However, in epidemiological studies, this should not be a problem. As
long as the assay is reliable, the ordering of the subjects by serum ENL
concentration is preserved. Because this is all that is required for studying a
marker-disease relationship, reliability, not accuracy, of the method is of primary
importance (Schulte et al. 1997). The results of the short TR-FIA can be
mathematically converted to correspond to the results of the basic TR-FIA. Both
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serum and heparin plasma samples are suitable for ENL measurements by the
short method. EDTA is a known interferent of TR-FIA because of its ability to
chelate the Europium label. Extraction excludes EDTA from the extract, and
EDTA plasma samples are thus available for the basic TR-FIA with extraction.
A disadvantage of TR-FIA, compared with the chromatographic methods,
is its inability to measure other lignans, such as END, and their metabolites.
In addition, TR-FIA is unable to separate the free ENL and the sulfate and
glucuronide conjugates from each other. Therefore, other methods are more
suitable for studies on the metabolism and kinetics of lignans.
Transitional studies
Because most cancers and many other chronic diseases take years or decades to
manifest clinically, in epidemiology, the most useful biological markers are those
with long elimination half-lives (Bernard 1995). The elimination half-life of ENL
is probably relatively short (Morton et al. 1997a, Nesbitt et al. 1999, Mazur et al.
2000), and thus, the extent of within-subject variation is essential. In epidemio-
logical studies, markers with large within-subject variation almost invariably show
weak associations with any given disease (Vineis 1997). A substantial fraction of
the absorbed mammalian lignans undergoes enterohepatic circulation, which
stabilizes serum levels of all compounds, including ENL (Bach Knudsen et al.
2003). However, notable within-subject variation was evident within one week
(II). Variation of such magnitude may cause attenuation of results in epidemio-
logical studies and must be taken into account in design of future studies. To
estimate the current ENL status within ±50% with 80% confidence requires three
serum or 24-h urine samples or 10 spot urine samples. For greater confidence or
precision, the number of samples must be higher. Study II did not explore the
effect of fasting time on ENL. The only study available on this topic did not find
any influence of fasting time between 0-12 h on serum ENL concentration (Hulten
et al. 2002). However, in Studies II-V all of the samples had been collected after
4 h - overnight fasting.
Serum and 24-h urine ENL measurements demonstrated similar short-term
within-subject variations. The advantages of serum, compared with urine
samples, include the more specific immunoassay method, as the immunoassay of
urine overestimates ENL excretion by 30% (Uehara et al. 2000b). In addition,
drawing blood is much easier than collecting 24-h urine. Although the
collection of spot urine samples is convenient, the spot urine ENL:creatinine
ratio showed low reliability, and therefore, is less suitable for epidemiological
studies than serum or 24-h urine samples. The spot urine samples were collected
with no timing requirements, and an overnight or 4-h urine sample may have
given better reliability.
The short-term reliability of serum ENL is quite similar in American and
Finnish populations (II) (Horner et al. 2002), and the short-term reliability of
overnight urine in Hawaiian volunteers resembles that of 24-h urine in Study II
59
(Franke et al. 2002). However, the long-term reliabilities of serum ENL in an
American population (Zeleniuch-Jacquotte et al. 1998) and of overnight urine
ENL:creatinine ratio in a Dutch population (den Tonkelaar et al. 2001) were
poorer than the short-term ones in Study II. Whether the same is true in the
Finnish population is unknown. The weakness of Study II was that the subjects
represented a homogeneous group of similar age and lifestyle. Applying these
results to the Finnish population at large should be done with caution.
Studies III-V were able to use only single measurements of serum ENL.
Intraindividual variation greatly attenuated the results of Study V. A similar
attenuation is probably present in Studies III and IV. These studies might have
found larger differences in ENL concentrations between the different dietary
groups had several serum samples from each subject been available.
Serum ENL concentrations vary markedly within populations and the
distribution of the concentrations is strongly skewed towards zero. The median
serum ENL concentrations here were 7.3 (II), 15.3 (III), 12.2 (IV), and 19.3
nmol/L (V). The results of Study III may explain the differences; serum ENL
concentrations in aged females were the highest and in young males the lowest.
Similarly, Study II with young student volunteers showed the lowest, and Study V
with mainly postmenopausal females the highest median ENL concentration. The
serum concentrations are in accordance with other large studies of Finnish sub-
jects (median serum ENL 15-24 nmol/L) ( Vanharanta et al. 1999, Uehara et al.
2000a, Stattin et al. 2002, Vanharanta et al. 2003, Kilkkinen et al. 2003b, 2004).
An early study suggested a very high correlation between grain intake and
urine ENL excretion in groups of women with different diets (Adlercreutz et al.
1986a). Study III did not confirm this association. Only in males did a weak
association exist between grain intake and serum ENL. The independent dietary
determinants of serum ENL for men were consumption of whole-grain products
and fruit and berries, and for women the consumption of vegetables. Two major
differences between these two studies can partly explain the disparity. First, the
former study analyzed four 72-h urine samples from each volunteer and
compared the mean ENL of the groups. This methodology minimizes the great
variation present in Study III. Second, the study population in the former study
included vegetarians and breast cancer patients, and the differences both in grain
intake and in ENL excretion between the extremities were huge. Study III, by
contrast, compared ENL concentrations and dietary differences within the
context of the typical Finnish diet, and did not therefore find such extreme
differences. Thus, the explanatory role of diet on the vast variation in ENL
appears to be minimal within an average population, in which nondietary
confounding factors play a major role.
Study IV indicated that high intake of fruit, berries, and vegetables can
increase median serum ENL concentration in a free-living population. This is in
accordance with previous findings in controlled, experimental conditions
(Hutchins et al. 1995, Kirkman et al. 1995). In Study IV, serum ENL concentra-
tions were highest at the end of the intervention period, indicating that adapta-
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tion of the microflora to high lignan intake takes at least three months. The
importance of the adaptation time has been confirmed by other studies as well
(Nesbitt et al. 1999, Jacobs et al. 2002, Tarpila et al. 2002). On the other hand,
despite the dietary changes, serum ENL concentration stayed below 10 nmol/L
in a quartile of the population even after 12 weeks of intervention.
The poor explanatory power of the diet for serum ENL concentrations in
Studies III and IV suggests that the non-dietary (confounding) factors may
determine individual ENL concentration reached. Study III indicated the four
factors: age (in women), BMI (in women), smoking (in women), and constipation
as subjective symptoms. All of these findings have later been confirmed by other
studies. Serum ENL concentrations are higher in aged than in young subjects
(III, Horner et al. 2002, Vanharanta et al. 2003). A possible explanation for this
finding is that in aged subjects the elimination of foreign compounds, such as
drugs, is slowed. In diabetic patients, serum ENL was positively associated with
the  severity  of  renal  disease  (von  Hertzen  et  al.  2004).  Serum  ENL
concentrations were higher in normal-weight than in under- or overweight women
(III, Horner et al. 2002, Hulten et al. 2002) or men (Horner et al. 2002,
Vanharanta et al. 2003). Although the difference in Study III could not be
explained by diet, overweight individuals might have overestimated their
consumption of healthy, lignan-containing food products. Further, a given
lignan intake may result in lower serum ENL concentrations in obese than in
normal-weight subjects because of the distribution of lignans to the fat tissue
(Rickard et al. 1998). Smoking lowers serum ENL concentration (III, Hulten et
al. 2002) by an unknown mechanism. Smoking can induce oxidizing enzymes
and affect ENL catabolism similar to estrogens (Berta et al. 1992). In addition,
cigarette smoke increases oxidative stress, and because ENL seems to function as an
antioxidant (Pool-Zobel et al. 2000, Prasad 2000, Saarinen et al. 2000, Vanha-
ranta et al. 2002b), the elimination of free radicals may consume ENL and lead to
lower serum ENL concentrations in smokers than in nonsmokers. Volunteers with
a subjective report of constipation show a higher serum ENL concentration than
asymptomatic ones (III, Vanharanta et al. 2003). The physiological explanation
for these findings remains obscure. Subjects with constipation may be speculated
to have slower intestinal motility, and as a result, the metabolism and absorption of
lignans are more complete than in asymptomatic subjects. Findings of the effect of
alcohol intake on serum ENL are inconsistent. Studies III and V showed no
association between alcohol intake and serum ENL, but reports on both positive
(Horner et al. 2002) and negative (Vanharanta et al. 2003) associations are also
available. This relation may depend on the type of alcohol consumed. Red wine,
for example, is known to contain a significant amount of lignans (Mazur 1998,
Nurmi et al. 2003b). Obviously, more studies on this subject are needed. The role
of intestinal microflora, however, seems fundamental. The use of antimicrobial
drugs may be one of the strongest confounders. Subjects receiving antimicrobial
treatment during the past three months were excluded in Studies II and III. The
effect of the antimicrobials may, however, last longer (Kilkkinen et al. 2002).
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Most of the extensive differences in serum ENL concentrations between
individuals remained unexplained. A better explanatory power between the
determinants and serum lignans might have been achieved if 1) ENL was
measured in several serum samples each subject, 2) the lignan measurement also
included other circulating lignans, END being the most important, 3) the FFQ
had been originally planned to assess plant lignan intake.
Enterolactone in breast cancer
Experimental animal studies provide strong evidence of a beneficial action of
lignans against mammary cancer (Thompson et al. 1996a, 1996b, Saarinen et al.
2000, 2001, 2002a, Chen et al. 2003a). In Study V, serum ENL was associated
with a reduced risk of breast cancer. This supports the findings of other case-
control studies (Adlercreutz et al. 1982, Ingram et al. 1997, Dai et al. 2002). By
contrast, only two of four later prospective studies found an inverse association
between ENL and risk of breast cancer (den Tonkelaar et al. 2001, Hulten et al.
2002, Boccardo et al. 2004, Kilkkinen et al. 2004).
Numerous explanations for the inconsistency exist. A major weakness of Study
V and the other case-control studies is the possibility that the disease process
influenced the level of ENL. Catabolic diseases, including malignancies, are known
to cause a decrease in serum total cholesterol (Iribarren et al. 1995). In a similar
manner, the cancer process may affect the metabolism of lignans. No follow-up
studies appear to have examined the effect of contracting cancer on serum ENL
levels. The within-subject variation in ENL is another major concern. With one
exception, all of the above studies measured ENL in only a single blood or urine
sample. Den Tonkelaar et al. (2001) did, however, use the mean of two overnight
urine samples. Nevertheless, the reliability in this study proved to be so poor that
the authors themselves suggested a substantial attenuation of their results and
questioned the significance of their findings. A serious weakness of all of the
available studies on the association between ENL and risk of breast cancer is the
lack of knowledge about recent antimicrobial treatments. Especially in studies
with an ENL measurement from only one sample, the absence of this informa-
tion may notably distort the results. Alcohol consumption is a known risk factor
of breast cancer (Singletary et al. 2001) and may have an association with ENL
concentration in serum (Horner et al. 2002, Vanharanta et al. 2003). Informa-
tion on alcohol intake should therefore be available, which was only the case in
Study V and in studies by Ingram et al. (1997) and Kilkkinen et al. (2004). In
these three studies, alcohol intake was not, however, associated with either breast
cancer or ENL.
The existing epidemiological studies on ENL and risk of breast cancer have
several drawbacks, and whether lignans truly offer protection against breast
cancer, remains an open question. The development of breast cancer,
postmenopausally, in particular, is a process requiring years or even decades. An
ENL measurement of a single serum or urine sample may not reflect the critical
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period of time. Based on animal studies, the critical time during which lignans
provide protection is childhood (Ward et al. 2000), which makes it very difficult
to study.
Several theories on the potential protective mechanisms of action of ENL are
available. Although it is unlikely that ENL acts through the estrogen receptors
(Saarinen et al. 2000), it may show its antiestrogenity via SHBG. An increase in
plasma SHBG concentration reduces the free circulating steroids, thus reducing
the bioavailability of estrogens (Adlercreutz 1990). Furthermore, SHBG is not
only a passive transporter of steroid hormones but also an active compound.
SHBG receptors are present in breast tissue and in estrogen-dependant MCF-7
breast cancer cells (Fortunati et al. 1999), and the binding of the SHBG-estro-
gen complex to its receptor decreases estrogen-induced cell growth (Rosner et al.
1999). Other possible modes of action of ENL include the reduction of IGF-I
(Rickard et al. 2000), antioxidative activity (Vanharanta et al. 2002b), and intra-
cellular competition for steroid enzymes (Evans et al. 1995).
ENL is a product of intestinal metabolism of plant lignans. But is ENL the
active molecule? A microflora capable of metabolizing lignans may also generate
other active metabolic products. These possible “side-products” form a largely
unknown area of research. One candidate for such a compound may be butyrate.
It confers protection against NMU-induced mammary carcinoma in rats
(Belobrajdic et al. 2000), and a dietary supplementation with rye was found to
increase the production of both fecal butyrate and serum ENL (McIntosh et al.
2003). Regardless of the identity of the molecule(s), the increase in the risk of
breast cancer following antimicrobial treatments (Knekt et al. 2000, Velicer et al.
2004) supports the hypothesis that the intestinal microflora plays a key role in
mammary carcinogenesis.
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Conclusions
Time-resolved fluoroimmunoassay proved to be a useful method for serum ENL
analysis.
Dietary variables were unable to explain the vast variation in serum ENL
concentrations in subjects consuming a typical Finnish diet. Nondietary factors,
by contrast, seem to play an important role in determining serum ENL concen-
tration. Serum ENL is therefore unsuited as a marker of dietary, including plant
lignan, intake. It may more appropriately be used as a measurement of body
exposure to mammalian lignans.
Of the known determinants of serum ENL, the gut microflora may be the
most important. In a standard diet, ENL can express differences well between
individuals in the ability of the microflora to convert plant lignans to mammalian
lignans. The importance of the intestinal microflora for mammalian lignan
formation leads to speculation that ENL may serve as a good marker of a func-
tional intestinal microflora. The profound effect of antimicrobials on the
END:ENL ratio suggests that this measurement may function as a biomarker of
intestinal function even better than ENL alone.
The value of single serum or urine ENL measurements as a biological marker
in epidemiology is limited. Single measurements face the problem of vast
individual variation, which may lead to attenuation of results. Epidemiological
studies should therefore measure ENL in several serum or urine samples.
Experimental animal studies strongly suggest a protective role for ENL against
breast cancer. This work strengthens the hypothesis; serum ENL was inversely
associated with breast cancer risk in a case-control study. However, since later
prospective studies have given conflicting results, this question remains open.
Clinical chemistry has many things to offer to this research field in future.
Important future tasks include:
1) finding a more stable marker for body exposure to mammalian lignans
than serum ENL. ENL concentration may be more stable in adipose tis-
sue, and therefore, adipose tissue ENL concentration could serve as a
better biological marker in cancer epidemiology.
2) developing and characterizing a biological marker of functional intestinal
microflora. This marker could, in addition to the END:ENL ratio,
include other compounds besides lignans.
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